Bardoxolone methyl was previously being investigated by Reata Pharmaceuticals, Inc. in partnership with Abbott Laboratories and Kyowa Hakko Kirin, as an experimental therapy for advanced chronic kidney disease (CKD) in type 2 diabetes mellitus patients.
In preliminary experiments, this investigational drug was reported to significantly increase estimated glomerular filtration rate (GFR), and improve several other markers of kidney function in patients with chronic kidney disease (CKD).
Torrent Pharmaceuticals | Emcure Pharmaceuticals | Barr Pharmaceuticals | Valeant Pharmaceuticals | Reata Pharmaceuticals | Millennium Pharmaceuticals | Anthera Pharmaceuticals | Quark Pharmaceuticals | Norwich Pharmaceuticals | Incepta Pharmaceuticals | Glenmark Pharmaceuticals |